Navigation Links
MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production
Date:10/16/2008

Second Agreement Signed in Third Quarter of 2008 Expands Worldwide

Application of Cutting-Edge Influenza Vaccine Technology

GAITHERSBURG, Md., Oct. 16 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome. This announcement marks the second agreement of this kind that MedImmune signed in the third quarter of 2008.

"Omninvest has demonstrated decades of commitment to providing protection against influenza, and we commend their commitment to donate some of their product to the World Health Organization (WHO) stockpile for distribution among developing nations," said MedImmune's Jonathan Klein-Evans, vice president, intellectual property. "MedImmune is pleased to license our reverse genetics technology to Omninvest as we have done previously to five other influenza vaccine manufacturers."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune has offered other influenza vaccine manufacturers non-exclusive licenses to these intellectual property estates for use in manufacturing seasonal or pandemic vaccines.

In a first for any influenza vaccine manufacturer, MedImmune applied the reverse genetics process to the development of its seasonal live, attenuated nasal spray influenza vaccine for the 2008-2009 season.

Since December of 2006, MedImmune has licensed its reverse genetics technology to CSL Limited of Australia, sanofi pasteur, Novartis, GlaxoSmithKline and BIKEN of Japan.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
2. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
5. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
6. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
7. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
8. Seneca Valley High School Student Receives Science Award From MedImmune
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... why mass flow controllers based on capillary thermal mass flow technology provide exponentially ... flow control applications. Over 80% of all industrial processes—such as those involving ...
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... premiere team-building and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking ... in California cuisine, and guests leave inspired with new cooking tips and techniques, ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):